Novartis AG

NVS-N

NYSE:NVS

85.89
0.77 (0.90%)
Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is one of the largest pharmaceutical companies by both market cap and sales.
More at Wikipedia

Analysis and Opinions about NVS-N

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
June 26, 2019
He sold it recently. They sold their eye-care division and are back to generic drugs, a lousy business for all companies. Invest elsewhere.
Show full opinionHide full opinion
Novartis AG (NVS-N)
June 26, 2019
He sold it recently. They sold their eye-care division and are back to generic drugs, a lousy business for all companies. Invest elsewhere.
HOLD
HOLD
July 5, 2018

$200 billion market cap. Fifty + drugs. None of them s over 6.5% of their revenue. They are spinning their ophthalmology business. Some positives there. He struggles to understand why the stock is down. Wouldn’t be his favorite European exposure but still well diversified solid business.

Show full opinionHide full opinion
Novartis AG (NVS-N)
July 5, 2018

$200 billion market cap. Fifty + drugs. None of them s over 6.5% of their revenue. They are spinning their ophthalmology business. Some positives there. He struggles to understand why the stock is down. Wouldn’t be his favorite European exposure but still well diversified solid business.

BUY
BUY
March 22, 2018

He likes it because of its exposure to Entresto, which cardiologists often call a wonder drug. The drug is relatively expensive ($9 per day) so the issue is getting insurance companies to pay for it. He thinks the runway for the drug is excellent and that it will become a blockbuster within a year or two. Pharma companies are under pressure because Trump is currently talking about reducing drug prices, but he (Grammer) is willing to wait on this stock.

Show full opinionHide full opinion
Novartis AG (NVS-N)
March 22, 2018

He likes it because of its exposure to Entresto, which cardiologists often call a wonder drug. The drug is relatively expensive ($9 per day) so the issue is getting insurance companies to pay for it. He thinks the runway for the drug is excellent and that it will become a blockbuster within a year or two. Pharma companies are under pressure because Trump is currently talking about reducing drug prices, but he (Grammer) is willing to wait on this stock.

TOP PICK
TOP PICK
November 20, 2017

It is a very big company with a pipeline of 13 drugs that are close to approves that could be blockbusters. They have drugs for heart failure that cardiologists are keen on. They have an eye care drug. They have a nice mixture of health care drugs. Pharma is unloved but that is an opportunity he can see. (Analysts’ target: $93.00).

Show full opinionHide full opinion
Novartis AG (NVS-N)
November 20, 2017

It is a very big company with a pipeline of 13 drugs that are close to approves that could be blockbusters. They have drugs for heart failure that cardiologists are keen on. They have an eye care drug. They have a nice mixture of health care drugs. Pharma is unloved but that is an opportunity he can see. (Analysts’ target: $93.00).

COMMENT
COMMENT
October 26, 2017

This has 3 things going for it. It is an international stock being Swedish, and European stocks have been stronger than US stocks for the 1st time in 10 years, and that should continue. Secondly, it is in healthcare which he likes. Thirdly, they’ve been doing a lot of research in immune boosting therapy, helping people fight cancer. This is going to be huge as we have so much further to go in fighting this scourge.

Show full opinionHide full opinion
Novartis AG (NVS-N)
October 26, 2017

This has 3 things going for it. It is an international stock being Swedish, and European stocks have been stronger than US stocks for the 1st time in 10 years, and that should continue. Secondly, it is in healthcare which he likes. Thirdly, they’ve been doing a lot of research in immune boosting therapy, helping people fight cancer. This is going to be huge as we have so much further to go in fighting this scourge.

HOLD
HOLD
September 14, 2017

They are joint ventured with Merck. Their oncology business is growing. Their dividend is stable. They are big pharma and you won’t see as much growth out of it. He is in it for the dividend.

Show full opinionHide full opinion
Novartis AG (NVS-N)
September 14, 2017

They are joint ventured with Merck. Their oncology business is growing. Their dividend is stable. They are big pharma and you won’t see as much growth out of it. He is in it for the dividend.

COMMENT
COMMENT
May 10, 2017

A value play that is run out of Switzerland with about a $200 billion market cap. There are 3 drivers to their business. There is the long-standing pharmaceuticals, they have the bio similar business, as well as Alcon for contact lenses. He likes the diversity. They have some key catalysts over the next couple of quarters. They are lacking in immuno ecology, cancer research, and there is speculation that they may sell one of their businesses in order to make an acquisition. Trading at 16X this year and down to just under 15X next year. Stable dividend. He likes this one very much.

Show full opinionHide full opinion
Novartis AG (NVS-N)
May 10, 2017

A value play that is run out of Switzerland with about a $200 billion market cap. There are 3 drivers to their business. There is the long-standing pharmaceuticals, they have the bio similar business, as well as Alcon for contact lenses. He likes the diversity. They have some key catalysts over the next couple of quarters. They are lacking in immuno ecology, cancer research, and there is speculation that they may sell one of their businesses in order to make an acquisition. Trading at 16X this year and down to just under 15X next year. Stable dividend. He likes this one very much.

WATCH
WATCH
April 24, 2017

The global pharma industry is under this cloud. The whole subsector is really struggling. They have come off their bottoms, but are working hard going sideways until we get more clarity on healthcare in the US.

Show full opinionHide full opinion
Novartis AG (NVS-N)
April 24, 2017

The global pharma industry is under this cloud. The whole subsector is really struggling. They have come off their bottoms, but are working hard going sideways until we get more clarity on healthcare in the US.

BUY
BUY
April 20, 2017

It is a really strong global pharma company. They are turning around their eye care business acquisition and their cardiac drug which had a bungled launch. If they are successful they will do quite well. It could be a blockbuster.

Show full opinionHide full opinion
Novartis AG (NVS-N)
April 20, 2017

It is a really strong global pharma company. They are turning around their eye care business acquisition and their cardiac drug which had a bungled launch. If they are successful they will do quite well. It could be a blockbuster.

WAIT
WAIT
September 14, 2016

Thinks pharmaceuticals had a rough bit of water, is the politics in the US. It hasn’t been resolved as to who is going to win. There has also been a lot of negativity around Valeant (VRX-N) and the whole sector, which is not done yet. Mrs. Clinton said she is going to clean this up. He would have a tendency to move his money somewhere else where there is more security.

Show full opinionHide full opinion
Novartis AG (NVS-N)
September 14, 2016

Thinks pharmaceuticals had a rough bit of water, is the politics in the US. It hasn’t been resolved as to who is going to win. There has also been a lot of negativity around Valeant (VRX-N) and the whole sector, which is not done yet. Mrs. Clinton said she is going to clean this up. He would have a tendency to move his money somewhere else where there is more security.

BUY
BUY
June 22, 2016

60% of their business is in pharmaceuticals, 20% in ophthalmology and 20% in Sandoz, a biosimilar company, the 1st one to get a biosimilar approved in the US. Attractive balance sheet.

Show full opinionHide full opinion
Novartis AG (NVS-N)
June 22, 2016

60% of their business is in pharmaceuticals, 20% in ophthalmology and 20% in Sandoz, a biosimilar company, the 1st one to get a biosimilar approved in the US. Attractive balance sheet.

PAST TOP PICK
PAST TOP PICK
March 18, 2016

(A Top Pick March 13/15. Down 22.73%.) This had swapped its businesses with Glaxo and the market didn’t like it. Also, there is a problem with the Swiss franc. However, you are still getting a 3.9% yield. A well-run drug company.

Show full opinionHide full opinion
Novartis AG (NVS-N)
March 18, 2016

(A Top Pick March 13/15. Down 22.73%.) This had swapped its businesses with Glaxo and the market didn’t like it. Also, there is a problem with the Swiss franc. However, you are still getting a 3.9% yield. A well-run drug company.

PARTIAL BUY
PARTIAL BUY
January 12, 2016

Suffering on the Pharma side like every other Pharma company. They are all having difficulty coming up with big blockbuster drugs. This company’s strong point is that it has a generic business that has done very well. Have a great business in eye care. He would step into this slowly. Not overly expensive.

Show full opinionHide full opinion
Novartis AG (NVS-N)
January 12, 2016

Suffering on the Pharma side like every other Pharma company. They are all having difficulty coming up with big blockbuster drugs. This company’s strong point is that it has a generic business that has done very well. Have a great business in eye care. He would step into this slowly. Not overly expensive.

BUY
BUY
January 7, 2016

Big, Swiss drug company. Pharma, contact lens, generics and OTC businesses. The growth prospects for the contact lens cleaner business is not good because of disposable contact lenses. They are thinking of selling it. The catalysts could be: guidance at the end of this month on 2016, a new heart medication being launched this year and a good pipeline which will get updated throughout the year.

Show full opinionHide full opinion
Novartis AG (NVS-N)
January 7, 2016

Big, Swiss drug company. Pharma, contact lens, generics and OTC businesses. The growth prospects for the contact lens cleaner business is not good because of disposable contact lenses. They are thinking of selling it. The catalysts could be: guidance at the end of this month on 2016, a new heart medication being launched this year and a good pipeline which will get updated throughout the year.

COMMENT
COMMENT
June 24, 2015

Healthcare. Has a decent vaccine business as well as a decent generics business. This would be a good solid hold. Organic growth will have to be a big part of the equation in order to continue to grow EPS. Good stock.

Show full opinionHide full opinion
Novartis AG (NVS-N)
June 24, 2015

Healthcare. Has a decent vaccine business as well as a decent generics business. This would be a good solid hold. Organic growth will have to be a big part of the equation in order to continue to grow EPS. Good stock.

Showing 1 to 15 of 39 entries

Novartis AG(NVS-N) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 1

Stockchase rating for Novartis AG is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Novartis AG(NVS-N) Frequently Asked Questions

What is Novartis AG stock symbol?

Novartis AG is a American stock, trading under the symbol NVS-N on the New York Stock Exchange (NVS). It is usually referred to as NYSE:NVS or NVS-N

Is Novartis AG a buy or a sell?

In the last year, 1 stock analyst published opinions about NVS-N. 0 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is DON'T BUY. Read the latest stock experts' ratings for Novartis AG.

Is Novartis AG a good investment or a top pick?

Novartis AG was recommended as a Top Pick by Lorne Steinberg on 2019-06-26. Read the latest stock experts ratings for Novartis AG.

Why is Novartis AG stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Novartis AG worth watching?

1 stock analyst on Stockchase covered Novartis AG In the last year. It is a trending stock that is worth watching.

What is Novartis AG stock price?

On 2020-06-05, Novartis AG (NVS-N) stock closed at a price of $85.89.